Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?

• Edgewise Therapeutics has dosed the first patient in EQUINOX-HFpEF, a Phase 2, randomized, double-blind, placebo-controlled trial of its oral cardiac sarcomere modulator EDG-15400 in adults aged 30 to 84 with symptomatic HFpEF and left ventricular ejection fraction of at least 50%.

• The trial extends Edgewise's cardiovascular discovery platform into HFpEF, a condition with limited targeted therapies, while upcoming HFSA 2026 presentations on EDG-15400's pharmacokinetics, pharmacodynamics and tolerability may provide further insight into its clinical potential.

• With first patient dosing in EQUINOX-HFpEF now achieved, we'll examine how this Phase 2 progression could reshape Edgewise's investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 92 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Edgewise Therapeutics Investment Narrative Recap

To own Edgewise Therapeutics, you need to believe its focused cardiac sarcomere platform, led by EDG-7500 in hypertrophic cardiomyopathy and EDG-15400 in HFpEF, can ultimately support meaningful revenue from successful late stage trials. The first patient dosed in EQUINOX-HFpEF is an incremental but important step for EDG-15400, yet the key near term catalyst still appears to be the planned Phase 3 start for EDG-7500 in Q4 2026, while prolonged losses without approvals remain the central risk.

Among recent announcements, the positive June 2026 CIRRUS-HCM Part D data for EDG-7500 is most relevant, because it underpins the Phase 3 program that currently anchors Edgewise's value story. Together with the new Phase 2 HFpEF trial for EDG-15400, this positions the company with two mid to late stage cardiac assets, but also heightens dependence on clean safety readouts and timely trial execution at a time when the business is still posting sizable net losses.

Yet against this progress, investors should also keep in mind the risk that prolonged unprofitable operations and any clinical setbacks could...

Read the full narrative on Edgewise Therapeutics (it's free!)

Edgewise Therapeutics' narrative projects $140.6 million revenue and $24.1 million earnings by 2029. This implies an earnings increase of about $221 million from -$197.2 million today.

Uncover how Edgewise Therapeutics' forecasts yield a $51.69 fair value , a 40% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$378.5 million of revenue by 2029, and they view the larger, longer Phase 2 HFpEF plan as a chance to build a richer dataset that could support premium pricing discussions, which is a far more optimistic take than the baseline narrative that simply frames EDG-15400 as pipeline diversification.